Market Overview:
The global cardiac autonomic neuropathy treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cardiac autonomic neuropathy, rising geriatric population, and technological advancements in the field of cardiac autonomic neuropathy treatment. However, factors such as high cost of treatment and lack of awareness about the disease are restraining the growth of this market. The global cardiac autonomic neuropathy treatment market is segmented on the basis of type, application, and region. On the basis of type, it is divided into solid oral and injectable segments. The solid oral segment dominates this market owing to its easy availability and low cost as compared to injectable drugs. On the basis on application, it is classified into hospitals, cardiology centers/clinics/outpatient clinics (COCs), ambulatory surgical centers (ASCs), and others including home care settings).
Product Definition:
Cardiac autonomic neuropathy (CAN) is a type of nerve damage that affects the heart. It can lead to problems with heart rate, blood pressure, and the way the heart pumps blood. CAN may cause shortness of breath, dizziness, or fainting. Treatment focuses on relieving symptoms and preventing further damage to the nerves.
Solid Oral:
Solid oral is a drug delivery system that enables the delivery of drugs to patients suffering from cardiac autonomic neuropathy (CAN) and it's used in the treatment of heart failure, which is one of the most common causes for mortality in patients with CAN. Solid oral dosage forms are available as tablets, capsules and powder.
Injectable:
Injectable is a drug that is administered by the route of injection into the vein. The drug works by increasing the electrical activity in heart muscles and can also prevent pain signals from reaching brain. In cardiac autonomic neuropathy treatment, injectable are used for treating symptoms of CAN such as low blood pressure, dry mouth, sweating, and diarrhea caused due to Cardiac Autonomic Nervous System (CANS) dysfunction.
Application Insights:
Based on application, the market is segmented into hospitals, cardiac centers and ambulatory surgical centers. The hospitals segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of patients suffering from CAD and increasing awareness about CANG. Furthermore, an increase in hospital admissions for cardiovascular diseases may also contribute to the growth of this segment during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of novel therapies, and favorable reimbursement policies. The increasing prevalence of cardiac disorders is also expected to boost demand for CANT devices in this region. According to a study published by National Center for Biotechnology Information (NCBI), around 6 million people are diagnosed with autonomic neuropathy annually in the U.S., which is approximately 1% population annually and accounts for huge economic burden due to loss of productivity and disability caused by variable intervals between attacks or episodes associated with various symptoms such as abdominal pain, diarrhea, orthostatic hypotension & syncope).
Growth Factors:
- Increasing incidence of cardiac autonomic neuropathy (CAN) due to increasing prevalence of diabetes and other underlying diseases
- Rising awareness about the symptoms and diagnosis of CAN
- Growing demand for better treatment options for CAN
- Technological advancements in the field of cardiac autonomic neuropathy treatment
- Availability of government funding for research on cardiac autonomic neuropathy
Scope Of The Report
Report Attributes
Report Details
Report Title
Cardiac Autonomic Neuropathy Treatment Market Research Report
By Type
Solid Oral, Injectable
By Application
Hospitals, Cardiac Centers, Ambulatory Surgical Centers
By Companies
Pfizer, Roche Holding, Novartis, Amgen, Privi Pharma, Silverline Chemicals, Anthem Biopharma, Praxis Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
180
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Cardiac Autonomic Neuropathy Treatment Market Report Segments:
The global Cardiac Autonomic Neuropathy Treatment market is segmented on the basis of:
Types
Solid Oral, Injectable
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Cardiac Centers, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Roche Holding
- Novartis
- Amgen
- Privi Pharma
- Silverline Chemicals
- Anthem Biopharma
- Praxis Pharmaceutical
Highlights of The Cardiac Autonomic Neuropathy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Solid Oral
- Injectable
- By Application:
- Hospitals
- Cardiac Centers
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cardiac Autonomic Neuropathy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cardiac autonomic neuropathy (CAN) is a condition that affects the nerves that control the heart's rhythm. CAN can cause problems with blood flow to the heart, which can lead to chest pain and other symptoms. Treatment for CAN typically includes medications and/or surgery.
Some of the key players operating in the cardiac autonomic neuropathy treatment market are Pfizer, Roche Holding, Novartis, Amgen, Privi Pharma, Silverline Chemicals, Anthem Biopharma, Praxis Pharmaceutical.
The cardiac autonomic neuropathy treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cardiac Autonomic Neuropathy Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cardiac Autonomic Neuropathy Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cardiac Autonomic Neuropathy Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cardiac Autonomic Neuropathy Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cardiac Autonomic Neuropathy Treatment Market Size & Forecast, 2018-2028
4.5.1 Cardiac Autonomic Neuropathy Treatment Market Size and Y-o-Y Growth
4.5.2 Cardiac Autonomic Neuropathy Treatment Market Absolute $ Opportunity
Chapter 5 Global Cardiac Autonomic Neuropathy Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
5.2.1 Solid Oral
5.2.2 Injectable
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cardiac Autonomic Neuropathy Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Cardiac Centers
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cardiac Autonomic Neuropathy Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cardiac Autonomic Neuropathy Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
9.6.1 Solid Oral
9.6.2 Injectable
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Cardiac Centers
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cardiac Autonomic Neuropathy Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
10.6.1 Solid Oral
10.6.2 Injectable
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Cardiac Centers
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cardiac Autonomic Neuropathy Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
11.6.1 Solid Oral
11.6.2 Injectable
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Cardiac Centers
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cardiac Autonomic Neuropathy Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
12.6.1 Solid Oral
12.6.2 Injectable
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Cardiac Centers
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cardiac Autonomic Neuropathy Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Type
13.6.1 Solid Oral
13.6.2 Injectable
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cardiac Autonomic Neuropathy Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Cardiac Centers
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cardiac Autonomic Neuropathy Treatment Market: Competitive Dashboard
14.2 Global Cardiac Autonomic Neuropathy Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Roche Holding
14.3.3 Novartis
14.3.4 Amgen
14.3.5 Privi Pharma
14.3.6 Silverline Chemicals
14.3.7 Anthem Biopharma
14.3.8 Praxis Pharmaceutical
